
AC Immune (ACIU) Stock Forecast & Price Target
AC Immune (ACIU) Analyst Ratings
Bulls say
AC Immune SA is advancing its pipeline of innovative therapies targeting neurodegenerative diseases with a focus on precision medicine through proprietary technology platforms. Notably, the company's PD active immunotherapy, ACI-7104.056, has shown a significant 20x increase in antibodies against pathogenic variants, with promising correlational results related to neuronal stability and CNS antibody levels. Additionally, the anticipated results from the ACI-24 plaque removal data are viewed as a pivotal catalyst that could position the company favorably in treating high-risk Alzheimer's disease patients.
Bears say
AC Immune SA reported a significant net operating loss of CHF 16.2 million for the most recent quarter, contributing to an annual net loss of CHF 70.4 million for the year 2025. The company is confronted with typical industry risks including potential negative clinical trial outcomes, safety concerns, and regulatory uncertainties that could severely impact its development programs. Additionally, the increasing complexity and price sensitivity of commercial markets for its product candidates raise further concerns about the company's financial sustainability and future profitability.
This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.
AC Immune (ACIU) Analyst Forecast & Price Prediction
Start investing in AC Immune (ACIU)
Order type
Buy in
Order amount
Est. shares
0 shares